Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax Inc.'s NVAX, +11.57% new COVID shot got a green light from the U.S. Food and Drug Administration Tuesday.

Novavax updated COVID vaccine gets FDA approval

Shares were up more than 10% on the news, which came more than three weeks after vaccines from Moderna and Pfizer.

Novavax Stock Jumps After FDA Approves Updated Covid Vaccine

The U.S. Food and Drug Administration on Tuesday authorized an updated version of Novavax's protein-based COVID-19 vaccine for emergency use in individuals aged 12 years and older, the health regulator said.

US FDA authorizes Novavax's updated COVID shot

Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.

FDA approves updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.

C3.ai

Carvana

As a CNBC report recently pointed out, some publicly traded enterprises are standing out but for the wrong reasons. Feeling the pressure from the specter of an extended period of heightened borrowing costs, hedge funds have placed some sizable bets against certain companies.

NVAX, AI, CVNA: The 3 Most Shorted Stocks This Month

ProKidney

Stock market investors are regularly monitoring highly shorted stocks, as the potential for an abrupt surge looms large.

Short squeeze alert for September 27th: 2 stocks that could skyrocket

Bionano Genomics

Nano-X Imaging

Biotech companies can offer some of the most explosive returns for an investor. Small-cap biotech companies are known to shoot up 100% overnight and also to dump 50% in an instant as well.

Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is Done

Novavax, Inc. stock has been facing a downward spiral, but there may be a short-term trading opportunity if FDA approval for its COVID-19 vaccine is positive. The high level of short interest in Novavax makes a short squeeze a possibility. Novavax's fundamental prospects beyond COVID-19, such as its NanoFlu influenza vaccine and R21/Matrix-M malaria vaccine, raise questions about its long-term sustainability.

Novavax: The Short Squeeze Story Isn't A Complete No-Brainer

European Medicines Agency director Emer Cooke said on Thursday the agency expects to make a decision on Novavax's updated COVID vaccine in October.

Europe expects to decide on Novavax's COVID vaccine in October

Moderna and Novavax both are focused on the coronavirus vaccine market of the future. The two companies each are developing vaccine candidates to prevent coronavirus and flu.

Does This Message From Moderna Mean Bad News for Novavax?

Invitae

It's important to approach high-risk, high-reward stocks with caution, and only consider them if you're comfortable with some risk. Novavax and Invitae both are risky right now, but they may be heading for better days.

You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

Nokia

Sirius XM Holdings Inc

Tencent Music Entertainment Group 

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Well-Known ‘Strong Buy' Stocks Under $10 Could Soar This Fall

Moderna

BA.2.86 is a new COVID variant health officials have been eyeing lately. But recent reports suggest that it may not be all that concerning.

Why COVID Vaccine Demand Might Not Be That Strong

Axcella Health Inc

Trading a short squeeze is a strategy where you find heavily shorted stocks and you wait for the short sellers to start covering their positions. This often pushes the price higher and beyond any real valuation.

Short squeeze alert for September 14th: Two stocks that could see remarkable gains

Novavax was an early coronavirus vaccine favorite but fell behind and missed out on the biggest revenue opportunity. Now it may enter the fall vaccine market later than rivals Pfizer and Moderna.

Novavax Is a Step Behind, Again. Should You Be Worried?

Cases of COVID-19 are rising and providing a tailwind for Novavax's stock. However, the biotech's prospects in this market are hard to pin down.

Up 20% in 1 Month, Is This Stock a Buy?

Pfizer

Novavax, Inc. (NASDAQ:NVAX) shares recovered some lost ground in Tuesday premarket trading after slumping almost 13% on Monday after it missed out on US Food and Drug Administration (FDA) approval for its new Covid-19 booster vaccine. The FDA signed off on updated jabs from Pfizer and its German partner BioNTech, and Moderna on Monday, with Novavax telling Reuters that its vaccine is still under review.

Novavax recovers from 13% slump after Pfizer and Moderna get a lead on Covid booster

Novavax stock crumbled Monday after the Food and Drug Administration signed off on updated Covid boosters from rivals Pfizer and Moderna.

Novavax Dives As Pfizer, Moderna Snag First Nods For Covid Boosters

Lucid Group

RumbleON

5 Former High-Flyer Stocks Trading Under $10 That Traders Are Pouncing On

Novavax stock is under pressure after the company beat second-quarter views, but trimmed its guide. Is NVAX stock a buy or a sell today?

Is Novavax Stock A Buy Or A Sell As Covid Hospitalizations Rise?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.

3 Stocks to Buy For the COVID Resurgence

Hookipa Pharma Inc

Invivyd Inc

Seelos Therapeutics

Zomedica

Amyris Inc

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

7 Biotech Stocks to Sell in September Before They Crash & Burn

Advanced Micro Devices

Invesco QQQ

September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.

Stocks on the Mend: A Mean Reversion Duo

Novavax once was a stock market winner, soaring in the early days of the coronavirus vaccine race. The company's vaccine reached the market behind rivals, and the stock price suffered.

News for Novavax Stock (NVAX)